Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and Progressive Tumours and Implications for Therapy
about
The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancerTreatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studiesNon-muscle invasive bladder cancer risk stratificationPrognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladderPatterns of care for early stage bladder cancer.Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancerThe natural history of secondary muscle-invasive bladder cancer.Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder.Timing of radical cystectomy in Central Europe - multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patientsQuality of care in patients with bladder cancer: a case report?Diagnostic value of urinary microRNAs as non-invasive biomarkers for bladder cancer: a meta-analysis.Previous Bladder Cancer History in Patients with High-Risk, Non-muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural HistoryOutcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genesAn evaluation of urinary microRNA reveals a high sensitivity for bladder cancer.Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer.Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?High expression of H3K27me3 is an independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomyCombining a molecular profile with a clinical and pathological profile: biostatistical considerationsRisk-adapted use of intravesical immunotherapy.High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility.A Pilot Study on the Potential of RNA-Associated to Urinary Vesicles as a Suitable Non-Invasive Source for Diagnostic Purposes in Bladder Cancer.Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.Developments in intravesical therapy for non-muscle-invasive bladder cancer.Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.Current intravesical therapy for non-muscle invasive bladder cancer.Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer.The emerging role of extracellular vesicles as biomarkers for urogenital cancers.Occupational risk factors for relapse-free survival in bladder cancer patients.Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin.Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA.Lymph node density in muscle-invasive transitional cell carcinoma of the urinary bladder; De novo versus progressive disease.Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis.Radical cystectomy for BCG failure: has the timing improved in recent years?
P2860
Q26770422-65485009-8801-433A-BFFF-691D9C87561FQ26775541-3CA3AC7F-0516-4182-B292-D790EBF8265CQ26775984-5819AE0A-E06A-485F-BC48-A35C3B267533Q33733739-1E87CC13-3B8E-4B2F-B774-88350CFF483CQ33875940-A71F7FC7-725F-409D-B822-6DBDAB65CFAEQ34203675-0DA245FB-AAF6-402C-B738-48DE2679DB8EQ34711282-97D3F553-AF5A-4C15-90E3-7CFB09EFD3FAQ34840601-AE5AB847-A10F-458E-BCE7-9C64C11FF0C7Q34965348-F5E37234-23EE-4B53-A2CE-8981847B4B05Q35533822-9D51A674-BE01-4981-A684-F0DEB4630561Q35541862-8F507381-9B39-4A70-B90B-F78D0EACBF69Q35858355-2EAFC22C-E8A4-43CC-B1F1-CC8386B0AB17Q35862328-F12D5D50-4A05-4B61-8386-09E3B6C50FF4Q36017213-E4A6E3CA-9522-4467-BB67-27EE5E8F1B11Q36075260-F4666B07-23A0-4456-86EB-528BBC67B7C9Q36093423-1548BB7B-6564-4D4C-A0A5-01D6E1AB6199Q36338886-C5310B53-436F-4971-A136-CA99694FF8CFQ36506715-9CD3BFC4-B647-492D-BE55-AD09227498A6Q36545629-81F3068B-8CD7-41B9-8FF9-9D7ECDEDD25AQ37053829-A3D1B36D-7C06-4B4F-9D28-D310A07668CCQ37182805-EC2398DB-3442-4FF8-9562-7577DA6A1A08Q37279010-F2A3966B-D8EE-4F24-BE15-9D9D48F71B04Q37335474-7FBB747D-2190-4245-A0FD-458CDD880B39Q37453816-2A8CE953-5ABD-41E2-817D-0D2FA50F305AQ37693488-1B573426-116E-45A7-ADCB-5E8965D9EEB5Q37697790-9B917CF2-3601-49A1-B7D5-1F0FFDF4C564Q37811051-01F73300-F6D8-401E-907F-F56122E23568Q37812604-85415B48-4468-4637-9933-9CB5FEF7F2A9Q37833152-235A0E4D-D820-4A62-837D-4D8B67FFBCC7Q38052445-BE51B385-7D1E-4642-9058-F0AF9E31A113Q38129947-5298E903-D392-4535-AE7D-3FD680BB3E2DQ38156190-3559A7A0-1CDC-46B1-BE4A-6333D84A1C3FQ38268801-D34A267A-B639-4A30-BCCC-5978F5D59C6FQ38404020-E834D44A-BE28-40BD-81CC-2A4A199F43CEQ39005578-FB3E7226-C689-4017-A37C-CF0B9C9C3BF0Q40116927-1040718C-B3FB-4D12-8574-429B04F1F29CQ41706346-E0D962C4-1BFA-4C38-9793-C1C5261A0354Q44209236-79CC0389-5ECC-4A5F-B473-EA06F575B6BDQ44529718-77AD6ED4-5228-43F6-A973-0547BBEAE686Q46216660-D4F40666-FC0E-4441-9CEC-FCC21538FECC
P2860
Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and Progressive Tumours and Implications for Therapy
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2004
@uk
name
Prognosis of Muscle-Invasive B ...... s and Implications for Therapy
@en
Prognosis of Muscle-Invasive B ...... s and Implications for Therapy
@nl
type
label
Prognosis of Muscle-Invasive B ...... s and Implications for Therapy
@en
Prognosis of Muscle-Invasive B ...... s and Implications for Therapy
@nl
prefLabel
Prognosis of Muscle-Invasive B ...... s and Implications for Therapy
@en
Prognosis of Muscle-Invasive B ...... s and Implications for Therapy
@nl
P2093
P1433
P1476
Prognosis of Muscle-Invasive B ...... s and Implications for Therapy
@en
P2093
Barthold Ph. Schrier
Bas W.G. van Rhijn
J. Alfred Witjes
Maarten P. Hollander
P304
P356
10.1016/J.EURURO.2003.10.006
P407
P577
2004-03-01T00:00:00Z